Type 2 diabetes: increased mortality with low HbA1c.
Five-year follow-up data from the Accord trial once again confirm that it is better to target an HbAlc level between 7% and 7.5% rather than a lower value, in patients with type 2 diabetes and a high risk of cardiovascular events.